TY - JOUR
T1 - Current and Future Management of Malignant Mesothelioma
T2 - A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
AU - Tsao, Anne S.
AU - Lindwasser, O. Wolf
AU - Adjei, Alex A.
AU - Adusumilli, Prasad S.
AU - Beyers, Matthew L.
AU - Blumenthal, Gideon M.
AU - Bueno, Raphael
AU - Burt, Bryan M.
AU - Carbone, Michele
AU - Dahlberg, Suzanne E.
AU - de Perrot, Marc
AU - Fennell, Dean A.
AU - Friedberg, Joseph
AU - Gill, Ritu R.
AU - Gomez, Daniel R.
AU - Harpole, David H.
AU - Hassan, Raffit
AU - Hesdorffer, Mary
AU - Hirsch, Fred R.
AU - Hmeljak, Julija
AU - Kindler, Hedy L.
AU - Korn, Edward L.
AU - Liu, Geoffrey
AU - Mansfield, Aaron S.
AU - Nowak, Anna K.
AU - Pass, Harvey I.
AU - Peikert, Tobias
AU - Rimner, Andreas
AU - Robinson, Bruce W.S.
AU - Rosenzweig, Kenneth E.
AU - Rusch, Valerie W.
AU - Salgia, Ravi
AU - Sepesi, Boris
AU - Simone, Charles B.
AU - Sridhara, Rajeshwari
AU - Szlosarek, Peter
AU - Taioli, Emanuela
AU - Tsao, Ming Sound
AU - Yang, Haining
AU - Zauderer, Marjorie G.
AU - Malik, Shakun M.
N1 - Publisher Copyright:
© 2018
PY - 2018/11
Y1 - 2018/11
N2 - On March 28– 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI–International Association for the Study of Lung Cancer– Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.
AB - On March 28– 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI–International Association for the Study of Lung Cancer– Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.
KW - Clinical trials
KW - Malignant mesothelioma
KW - Multimodality therapy
KW - Pleural
KW - Targeted therapy
UR - https://www.scopus.com/pages/publications/85055270710
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000450088600018&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1016/j.jtho.2018.08.2036
DO - 10.1016/j.jtho.2018.08.2036
M3 - Article
C2 - 30266660
SN - 1556-0864
VL - 13
SP - 1655
EP - 1667
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 11
ER -
SDG 3 Good Health and Well-being